| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $64.9M | — | +223.6% |
| R&D Expense | $58.8M | — | -4.5% |
| SG&A Expense | $37.6M | — | -8.4% |
| Operating Income | -$34.2M | — | +59.2% |
| Income Tax | $0 | — | — |
| Net Income | -$42.7M | — | +49.7% |
| EPS (Basic) | -$0.48 | — | +51.0% |
| EPS (Diluted) | -$0.48 | — | +51.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $130.9M | -3.0% | -15.0% |
| Short-term Investments | $221.2M | -14.7% | -38.3% |
| Accounts Receivable | $38.1M | +0.3% | +142.4% |
| Inventory | $34.9M | +6.7% | +649.3% |
| Current Assets | $471.2M | -10.8% | -14.1% |
| Total Assets | $472.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$50.3M | — | +47.1% |
| Investing Cash Flow | $38.4M | — | -59.2% |
| Financing Cash Flow | $7.9M | — | +751.4% |
| -26.2% |
| Current Liabilities | $86.2M | -28.3% | -8.9% |
| Total Liabilities | $431.0M | -7.3% | +1.3% |
| Stockholders' Equity | $41.6M | -35.6% | -80.6% |